ECE2024 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (383 abstracts)
Weight reduction in patients with hypothalamic obesity treated with setmelanotide for 12 months
Christian L. Roth 1 , Ashley Shoemaker 2 , Michael Gottschalk 3 , Jennifer Miller 4 , Guojun Yuan 5 , Sonali Malhotra 6 , Cecilia Scimia 5 & M. Jennifer Abuzzahab 7
1Seattle Children’s Research Institute; Division of Endocrinology, Department of Pediatrics, University of Washington, Seattle, Seattle, United States; 2Ian Burr Division of Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, United States; 3Pediatric Endocrinology, University of California San Diego/Rady Children’s Hospital, San Diego, United States; 4Pediatric Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, Gainesville, United States; 5Rhythm Pharmaceuticals, Inc., Boston, United States; 6Rhythm Pharmaceuticals, Inc.; Harvard Medical School; Massachussetts General Hospital, Boston, United States; 7Pediatric Endocrinology and Diabetes, Children’s Minnesota, Saint Paul, United States
Background: Hypothalamic obesity (HO) is an acquired form of severe obesity characterized by rapid and excessive weight gain resulting from insult to the hypothalamus—primarily caused by tumor invasion, resection, or radiotherapy—that can impair melanocortin-4 receptor (MC4R) pathway signaling. Treatment with setmelanotide, an MC4R agonist, resulted in weight and hunger reduction at 16 weeks in a Phase 2 trial of patients with HO. Here, we report changes in weight-related parameters after 12 months of setmelanotide treatment in patients with HO who entered a long-term extension (LTE) trial.
Methods: The Phase 2, multicenter, open-label study (NCT04725240) was a 16-week trial in patients aged ≥6 to ≤40 years with a clinical diagnosis of HO. Patients who demonstrated adequate safety and meaningful clinical benefit were eligible to enroll in the LTE trial (NCT03651765). Mean (standard deviation [SD]) percent change in body mass index (BMI) for all patients and mean (SD) change in percent of the 95th BMI percentile (%BMI95) for children (aged <18 years) from index trial baseline to Month 12 of setmelanotide treatment were assessed.
Results: Of 14 patients who entered the LTE, 12 (86%) received ≥12 months of setmelanotide at the time of analysis. One adult who experienced nausea discontinued study drug at 7 months and 1 child who had been lost to follow-up reconsented and reentered the LTE but did not have 12-month data. At Month 12, the mean (SD) percent BMI change from baseline was −24.9% (13.0%) across all patients (n=12) and in children (n=11), the mean (SD) change in %BMI95 was −39.5 (19.4) percentage points. No new safety signals were identified.
Conclusions: In a heterogeneous population of patients with HO secondary to treatment of hypothalamic tumors, 12 months of setmelanotide treatment was associated with sustained meaningful BMI improvement with no new safety signals.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more